Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

MONTREAL, Nov. 2, 2012 /PRNewswire/ --

  • 2012 Third Quarter Total Revenue $884 million
  • Organic growth (same store sales) was approximately 14%
  • Pro forma organic growth was approximately 12%
  • 2012 Third Quarter GAAP EPS $0.02; Cash EPS $1.15
  • 2012 Third Quarter GAAP Cash Flow from Operations was $167 million; Adjusted Cash Flow from Operations was $241 million
  • Updated Guidance for 2012:
  • Narrowing Cash EPS guidance for the fourth quarter to $1.30 to $1.35, which excludes new interest expense of $0.12 from $2.75 billion Medicis related financing
  • Previous Guidance for the fourth quarter was $1.25 to $1.45 Cash EPS
  • Lowering Adjusted Cash Flow from Operations from greater than $1.4 billion to $1.2 to $1.3 billion due to the increased investment in working capital
  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces third quarter financial results for 2012.

    "The third quarter results again demonstrate our ability to deliver strong growth and profitability," said J. Michael Pearson, chairman and chief executive officer.  "We are very pleased with the third quarter's double-digit organic growth and record Cash EPS.  Our U.S. Dermatology business had an outstanding quarter, the trends in our U.S. Neurology and Other business are clearly improving, and our businesses outside the U.S. continue to perform strongly.  This continued strength in our base business, coupled with the potential approval of efinaconazole (IDP-108) and the pending acquisition of Medicis, should provide us with a solid foundation to deliver strong continued growth in 2013 and beyond."

    Business PerformanceValeant's business continued to perform well in the third quarter of 2012 with all businesses achieving results within or above expectations.  Same store organic growth was
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
    (Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
    (Date:7/21/2014)...   Aventura , the leader for instant-on ... that MemorialCare Health System , a top ... at the Orange Coast Memorial Medical Center ... Orange Coast Memorial is a 218-bed general medical ... annually. The Aventura Roaming Aware Desktop (RAD) – ...
    Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
    ... 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that ... Company's prostate cancer drug candidate CB7630,(abiraterone acetate) were ... Conference, which is currently taking place,in Lugano, Switzerland. ... presentations on Sunday, July 8, as part of ...
    ... Factor Xa Inhibitor,Shows a Significant Reduction in ... Enoxaparin with Similarly Low Bleeding,Rates , GENEVA, ... clinical trial,data presented today at the XXI ... demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior efficacy ...
    Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
    (Date:7/22/2014)... 22, 2014 Recently, 2014quinceaneradresses.com, a popular ... its latest assortment of blue and white Quinceanera ... on these special Quinceanera gowns, hoping to show appreciation ... 30 can get a discounted price, up to 60% ... to announce these new items. As one of the ...
    (Date:7/22/2014)... South Carolina (PRWEB) July 22, 2014 One ... loss solution managed to lose 20 pounds. Unfortunately, the weight ... and nauseated for the duration of her time using the ... One woman experienced heart flutters and insomnia as a result ... experienced a heart attack at the age of 37 because ...
    (Date:7/22/2014)... IL (PRWEB) July 22, 2014 Hope ... of Matthew Baffoe to their Chicago staff. This addition ... Taff Construction Incorporated (TCI). Hope For The Warriors® is ... members, their families, and families of the fallen who ... of duty. , Baffoe’s work will support programs ...
    (Date:7/22/2014)... Garland’s new Energizer BK specially ... as a flood coat over new and existing asphalt ... restoration material. It provides natural resistance to moisture, chemicals, ... life-cycle costs. Energizer BK is specially formulated with an ... in addition to superior strength and flexibility. , ...
    (Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
    Breaking Medicine News(10 mins):Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2
    ... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
    ... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
    ... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
    ... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
    ... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
    ... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
    Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
    ... contain a buffered sodium citrate ... a citrate concentration of 0.109 ... (3.8%). The mixing ratio is ... 9 parts blood. In addition ...
    ... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
    Inquire...
    ... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
    Medicine Products: